keyword
coxsackieviru
proteas
enzym
kinet
noncompetit
inhibitor
benserazid
alloster
bind
site
b
r
c
coxsackieviru
main
caus
human
viral
myocard
cardiomyopathi
viral
encod
coxsackieviru
proteas
pro
play
essenti
role
viral
prolifer
benserazid
discov
novel
inhibitor
drug
librari
screen
target
coxsackieviru
pro
use
fretbas
enzym
assay
benserazid
whose
chemic
structur
electrophil
function
group
character
noncompetit
inhibitor
enzym
kinet
studi
molecular
dock
studi
benserazid
analog
indic
novel
put
alloster
bind
site
involv
specif
moieti
determin
key
pharmacophor
enzym
inhibitori
activ
suggest
put
alloster
bind
site
may
novel
target
futur
therapeut
strategi
human
coxsackievirus
cv
belong
picornaviru
famili
nonenvelop
positivesens
singlestrand
rna
virus
among
coxsackieviru
common
caus
human
viral
myocard
acut
myocard
typic
result
heart
failur
children
adolesc
often
progress
chronic
myocard
dilat
cardiomyopathi
annual
approxim
symptom
viral
myocard
heart
transplant
caus
infect
upon
viral
infect
positivestrand
rna
genom
releas
host
cell
translat
larg
polyprotein
precursor
undergo
success
proteolyt
cleavag
process
gener
function
viral
protein
structur
protein
proteolyt
process
polyprotein
essenti
product
compon
virion
primarili
gener
two
viral
encod
proteas
picornaviru
proteas
particular
essenti
multifunct
protein
http
feder
european
biochem
societi
publish
elsevi
bv
right
reserv
abbrevi
cosxackieviru
pro
cosxackieviru
proteas
fret
fluoresc
reson
energi
transfer
ldopa
levodopa
boc
tertbutyloxycarbonyl
tfa
trifluoroacet
acid
dcm
dichloromethan
ic
half
maxim
inhibitori
concentr
h
nmr
proton
nuclear
magnet
reson
spectroscopi
requir
major
proteolyt
cleavag
event
occur
viral
replic
also
target
sever
host
protein
eukaryot
translat
initi
factor
g
cleavag
stimul
factor
halt
host
protein
synthesi
induc
apoptosi
essenti
role
proteas
viru
replic
drawn
attent
attract
target
develop
antivir
therapeut
agent
effect
therapeut
strategi
prevent
treatment
diseas
caus
infect
current
avail
mani
picornaviru
proteas
like
proteas
inhibitor
develop
mani
research
group
previou
studi
among
varieti
proteas
inhibitor
recent
report
screen
compound
librari
design
compound
base
structur
substrat
act
activ
site
although
numer
proteas
inhibitor
develop
therapeut
agent
infect
antivir
drug
approv
date
treatment
infect
human
exampl
compound
ref
peptidomimet
inhibitor
k
lm
interact
activ
site
cvb
pro
whose
bind
mode
determin
crystal
compound
ref
discov
random
screen
nonpeptid
multifunct
inhibitor
ic
lm
pro
pro
sarscov
pro
group
report
peptidomimet
inhibitor
ref
ic
nm
deriv
lactam
ring
modifi
glutamin
residu
ethyl
ester
group
modifi
isoquinolin
moieti
bunsatur
carbonyl
compound
known
undergo
electrophil
irrevers
coval
interact
cystein
residu
activ
site
fig
although
coval
bind
provid
strong
irrevers
inhibit
electrophil
natur
pro
inhibitor
increas
offtarget
safeti
risk
possibl
interact
host
cystein
proteas
therefor
critic
unmet
need
field
discoveri
alloster
revers
inhibitor
pro
reduc
side
effect
herein
report
first
discoveri
noncompetit
inhibitor
pro
interact
put
alloster
bind
site
screen
drug
compound
librari
intend
explor
new
chemic
class
pro
inhibitor
also
present
studi
enzym
kinet
molecular
dock
character
inhibitor
pro
gene
transform
vector
express
escherichia
coli
strain
pro
purifi
chitin
column
chromatographi
use
impact
system
new
england
bio
lab
beverli
ident
pro
confirm
sodium
dodecyl
sulphatepolyacrlamid
gel
electrophoresi
sdspage
base
size
almost
purifi
pro
maintain
hepe
buffer
mm
hepe
mm
nacl
mm
edta
mm
dtt
ph
vv
glycerol
enzymebas
assay
enzym
assay
perform
micropl
overal
reaction
volum
compris
reaction
buffer
mm
trishcl
mm
dtt
igep
water
enzym
kinet
experi
perform
use
follow
method
pro
mix
differ
concentr
benserazid
lm
final
volum
min
mixtur
place
micropl
triplic
three
microlit
differ
concentr
fluorogen
substrat
lm
also
ad
respect
well
reaction
incub
enzym
activ
monitor
everi
min
spectrofluoromet
bio
teck
instrument
inc
usa
period
h
initi
veloc
determin
linear
section
michaelismenten
plot
data
easili
fit
sigmaplot
program
spss
san
diego
ca
usa
revers
inhibit
determin
measur
recoveri
enzymat
activ
larg
rapid
dilut
enzymeinhibitor
complex
concentr
ic
valu
inhibitor
benserazid
compound
enzym
preincub
min
equilibr
time
mixtur
dilut
reaction
buffer
contain
fluorogen
substrat
lm
initi
enzym
reaction
enzym
activ
monitor
everi
min
spectrofluoromet
bio
teck
instrument
inc
usa
period
h
revers
plot
fit
sigmaplot
program
spss
san
diego
ca
usa
molecular
dock
studi
benserazid
perform
base
xray
crystal
structur
pro
pdb
code
dopadecarboxylas
pdb
code
alloster
bind
site
noncompetit
inhibitor
benserazid
sought
detect
caviti
use
eras
algorithm
method
possibl
alloster
bind
site
found
molecular
dock
studi
site
perform
use
cdoker
charmm
forcefieldbas
dock
tool
discoveri
studio
accelri
inc
san
diego
ca
usa
process
cdoker
workflow
follow
use
hightemperatur
molecular
dynam
find
possibl
ligand
conform
random
rotat
ligand
rigid
receptor
gridbas
simul
anneal
full
energi
minim
output
refin
ligand
pose
sort
cdoker
energi
moieti
benserazid
replac
bf
dihydroxi
benzyl
monohydroxi
benzyl
gi
benzyl
moieti
j
follow
synthet
procedur
illustr
scheme
benserazid
deriv
synthes
start
tertbutyl
react
hydrazin
hydrat
excess
amount
methanol
yield
compound
conjug
reaction
compound
variou
hydroxybenzaldehyd
remov
acetonid
subsequ
deprotect
boc
group
afford
hydrazon
deriv
final
compound
synthes
hydrogen
inhibitori
effect
benserazid
deriv
pro
summar
tabl
screen
druglik
compound
librari
use
fretbas
enzym
assay
pro
identifi
initi
hit
compound
select
benserazid
final
effect
compound
ic
valu
lm
pro
benserazid
commerci
drug
develop
roch
manag
parkinson
diseas
combin
ldopa
levodopa
cobeneldopa
ban
unabl
cross
bloodbrain
barrier
thu
drug
peripher
inhibit
aromat
lamino
acid
decarboxylas
aadc
dopa
decarboxylas
structur
benserazid
quit
differ
known
inhibitor
act
activ
site
pro
perform
enzym
kinet
studi
determin
mechan
inhibit
benserazid
pro
effect
benserazid
enzym
kinet
pro
illustr
fig
michaelismenten
plot
fig
v
max
valu
reduc
presenc
benserazid
concentrationdepend
manner
without
chang
k
valu
lm
suggest
benserazid
noncompetit
inhibitor
lineweaverburk
plot
fig
shown
fig
dixon
plot
versu
also
result
famili
straight
line
xaxi
intercept
reflect
noncompetit
inhibit
pro
k
valu
calcul
lm
figur
explain
introduct
certain
known
noncompetit
inhibitor
act
activ
site
pro
coval
interact
howev
benserazid
electrophil
function
group
coval
interact
therefor
alloster
bind
site
benserazid
exist
confirm
revers
alloster
inhibit
mechan
benserazid
revers
test
perform
convent
protocol
use
larg
rapid
dilut
inhibitor
shown
fig
partial
inhibit
condit
full
inhibit
high
concentr
inhibitor
benserazid
concentr
ic
valu
suggest
mode
enzym
inhibitori
activ
benserazid
display
revers
pattern
irrevers
inhibitor
compound
show
typic
irrevers
pattern
enzym
inhibit
silico
search
put
alloster
bind
site
molecular
dock
studi
compound
benserazid
analog
therefor
pursu
determin
novel
put
alloster
bind
site
pro
use
silico
studi
among
caviti
detect
use
eras
algorithm
method
avail
commerci
silico
softwar
discoveri
studio
accelri
inc
san
diego
ca
put
alloster
bind
site
fit
size
benserazid
select
posit
opposit
activ
site
fig
compos
residu
fig
bind
mode
benserazid
deriv
bind
pocket
investig
molecular
dock
studi
fig
specul
group
compound
benserazid
may
interact
hydrogen
bond
side
chain
side
chain
carbonyl
oxygen
back
bone
respect
carbonyl
oxygen
benserazid
may
interact
guanidin
moieti
oh
nh
group
benserazid
may
also
form
hydrogen
bond
guanidin
moieti
fig
cdoker
energi
bind
mode
compound
similar
benserazid
fig
cdoker
energi
compound
also
exhibit
inhibitori
effect
ic
lm
similar
benserazid
case
dihydroxi
benzyl
bf
monohydroxi
benzyl
gi
benzyl
j
substitut
compound
enzym
inhibitori
activ
complet
lost
bind
mode
analog
suggest
decreas
hydrogen
bond
interact
fig
cdoker
energi
fig
cdoker
energi
compar
compound
fig
may
detriment
effect
enzym
inhibitori
activ
therefor
moieti
may
critic
import
bind
evok
inhibit
enzym
catalysi
compar
bind
mode
benserazid
pro
dopadecarboxylas
use
silico
molecular
dock
studi
sinc
benserazid
potent
inhibitor
dopa
decarboxylas
analyz
possibl
bind
mode
benserazid
dopa
decarboxylas
dock
studi
shown
fig
one
phenol
hydroxyl
group
benserazid
might
interact
interact
hydrazin
moieti
carbidopa
fig
supplementari
inform
addit
serin
moieti
benserazid
detect
form
hydrogen
bond
via
water
molecul
carboxyl
group
carbidopa
similar
interact
seem
import
bind
moieti
benserazid
might
differ
proteas
fig
dopa
decarboxylas
fig
trihydroxyl
group
serin
group
respect
therefor
modif
serin
moieti
benserazid
substitut
amin
hydroxyl
group
chang
nonpolar
group
may
provid
select
inhibit
proteas
avoid
potenti
side
effect
may
caus
inhibit
decarboxylas
enzym
herein
report
novel
noncompetit
pro
inhibitor
benserazid
known
antiparkinson
diseas
drug
discov
screen
use
fretbas
enzym
assay
mechan
enzym
inhibit
bind
mode
benserazid
deriv
character
enzym
kinet
silico
molecular
dock
studi
studi
demonstr
benserazid
noncompetit
inhibitor
interact
put
alloster
bind
site
moieti
benserazid
import
inhibitori
action
cvb
pro
result
suggest
new
therapeut
strategi
target
newli
found
presenc
variou
concentr
substrat
inhibitor
pro
activ
measur
fluoresc
xaxi
substrat
concentr
yaxi
pro
activ
rfu
min
plot
describ
differ
inhibitor
concentr
lm
lm
lm
j
lm
lm
b
lineweaverburk
plot
benserazid
concentr
set
lm
lm
lm
j
lm
lm
xaxi
concentr
yaxi
pro
activ
rfu
min
c
dixon
plot
substrat
concentr
set
lm
lm
j
lm
xaxi
inhibitor
concentr
yaxi
pro
activ
min
revers
plot
xaxi
time
yaxi
product
fluoresc
benserazid
concentr
set
lm
compound
concentr
set
nm
put
alloster
bind
site
cvb
pro
could
appli
develop
noncompetit
inhibitor
